Anidulafungin

Hospital Pharmacy

Volumn 41, Issue 7, 2006, Pages 669-680

  Cada, Dennis J ^b   Levien, Terri ^a   Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67651024881     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4107-669     Document Type: Review

References (62)

1. Eraxis [package insert]. New York, NY: Pfizer Inc.; 2006.
2. Mycamine [package insert]. Deerfield, IL: Astellas Pharma US, Inc.; 2005.
3. Cancidas [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2005.
4. Arevalo MP, Carrillo-Munoz AJ, Salgado J, et al. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother. 2003;51:163-166.
5. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol. 2003;20:121-136.
6. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother. 2006;57;705-708.
7. Roling EE, Klepser ME, Wasson A, Lewis RE, Ernst EJ, Pfaller MA. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Cryptococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis. 2002;43:13-17.
8. Cuenca-Estrella M, Mellado E, Diaz-Guerra TM, Monzon A, Rodriguez-Tudela JL. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. J Antimicrob Chemother. 2000;46:475-477.
9. Moore CB, Oakley KL, Denning DW. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect. 2001;7:11-16.
10. Marco F, Pfaller MA, Messer SA, Jones RN. Activity of MK-0991 (L- 743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn Microbiol Infect Dis. 1998;31:33-37.
11. Zhanel GG, Karlowsky JA, Zelenitsky SA, Turik MA, Hoban DJ. Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other antifungal agents. Antimicrob Agents Chemother. 1998;42:2446-2448.
12. Uzun O, Kocagoz S, Cetinkaya Y, Arikan S, Unal S. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob Agents Chemother. 1997;41:1156-1157.
13. Zhanel GG, Karlowsky JA, Harding GA, et al. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother. 1997;41:863-865.
14. Pfaller MA, Hollis R, Goldstein BP, Messer S, Diekema D, Henkel T. In vitro activity of anidulafungin (ANID) and other agents against 526 esophageal candidiasis (EC) isolates. Abstract M- 1226 presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL.
15. Messer SA, Kirby JT, Sader HS, Fritsche TR, Jones RN. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J Antimicrob Chemother. 2004;54:1051-1056.
16. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol. 2005;43:5425-5427.
17. Chavez M, Bernal S, Valverde A, Gutierrez MJ, Quindos G, Mazuelos EM. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J Antimicrob Chemother. 1999;44:697-700.
18. Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother. 2000;44:1108-1111.
19. Karlowsky JA, Hoban DJ, Zhanel GG, Goldstein BP. In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. Int J Antimicrob Agents. 2006;27:174-177.
20. Moore CB, Denning DW. Tolerance and fungicidality in vitro of caspofungin, micafungin and anidulafungin against Candida guilliermondii. Abstract M-230 presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, CA.
21. Marco F, Danes C, Almela M, et al. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001). Diagn Microbiol Infect Dis. 2003;46:259-264.
22. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob Agents Chemother. 2004;48:1912-1915.
23. Serrano MdelC, Valverde-Conde A, Chavez MM, et al. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn Microbiol Infect Dis. 2003;45:131-135.
24. Oakley KL, Moore CB, Denning DW. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother. 1998;42:2726-2730.
25. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis. 1998;30:251-255.
26. Philip A, Odabasi Z, Rodriguez JR, et al. In vitro synergy testing of anidula-fungin (ANID) with itraconazole (ITR) and voriconazole (VOR) against Aspergillus spp. and Fusarium spp. Abstract A-2 presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL.
27. Stevens DA. Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens. Antimicrob Agents Chemother. 2000;44:2547-2548.
28. Philip A, Odabasi Z, Rodriguez J, et al. In vitro synergy testing of anidula-fungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005;49:3572-3574.
29. Ostrosky-Zeichner L, Matar M, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In-vitro synergy testing of anidulafungin (AFG) and micafungin (MFG) in combination with amphotericin B (AMB) against Aspergillus spp. and Fusarium spp. Abstract M-1816 presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, CA.
30. Petraitis V, Petraitiene R, Groll AH, et al. Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother. 2001;45:471-479.
31. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother. 1999;43:2148-2155.
32. Gumbo T, Louie A, Liu W, Deziel M, Drusano MF, Drusano GL. Relative efficacies of anidulafungin, fluconazole, and amphotericin B for treatment of disseminated Candida glabrata in neutropic mice. Abstract A-2 presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL.
33. Petraitis V, Petraitiene R, Groll AH, et al. Antifungal efficacy, safety, and single- dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 1998;42:2898-2905.
34. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother. 2000;44:3381-3388.
35. Verweij PE, Oakley KL, Morrissey J, Morrissey G, Denning DW. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother. 1998;42:873-878.
36. Li C, Fleisher D, Li L, et al. Regional- dependent intestinal absorption and meal composition effects on systemic availability of LY303366, a lipopeptide antifungal agent, in dogs. J Pharm Sci. 2001;90:47-57.
37. Dowell J, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. A population pharmacokinetic analysis of anidulafungin. Abstract A-1575 presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL.
38. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol. 2004;44:590-598.
39. Dowell J, Stogniew M, Krause D, Henkel T. Anidulafungin (ANID) pharmacokinetic (PK) / pharmacodynamic (PD) correlation: treatment of esophageal candidiasis (EC). Abstract A-1578 presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL.
40. Stogniew M, Pu F, Henkel T, Dowell J. Anidulafungin biotransformation in humans is by degradation not metabolism. Abstract P1223 presented at: 13th European Congress of Clinical Microbiology and Infectious Diseases; May 10-13, 2003; Glasgow, UK.
41. Dowell J, Pu F, Lee J, Stogniew M, Krause D, Henkel T. A clinical mass balance study of anidulafungin (ANID) and showing complete fecal elimination. Abstract A-1576 presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL.
42. Dowell J, Stogniew M, Krause D. Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment. Abstract P1222 presented at: 13th European Congress of Clinical Microbiology and Infectious Diseases; May 10-13, 2003; Glasgow, UK.
43. Thye D, Kilfoil T, White RJ, Lasseter K. Anidulafungin: pharmacokinetics in subjects with mild and moderate hepatic impairment. Abstract A-34 presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, IL.
44. Thye D, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: pharmacokinetics (PK) in subjects with severe hepatic impairment (HI). Abstract A-1392 presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, CA.
45. Thye D, Marbury T, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: pharmacokinetics in subjects receiving hemodialysis. Abstract A-1390 presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, CA.
46. Thye D, Marbury T, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: pharmacokinetics in subjects with renal impairment. Abstract A-1391 presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, CA.
47. Benjamin DK, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother. 2006;50:632-638.
48. Krause DS, Henkel T, Goldstein BP, Walsh TJ. Anidulafungin (ANID) vs. fluconazole (FLU) in esophageal candidiasis (EC): a phase 3, randomized, doubleblind, multicenter trial. Abstract M- 1760 presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL.
49. Versicor announces positive phase III clinical trial results with anidulafungin for esophageal candidiasis [press release]. King of Prussia, PA: Versicor Inc.; March 17, 2003. Available at: d=1027. Accessed April 6, 2006.
50. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, doubleblind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis. 2004;39:770-775.
51. Krause D, Goldstein B, Wible M, Kilfoil G, Henkel T. A phase 2 dose-ranging study of the safety and efficacy of anidulafungin in invasive candidiasis. Abstract 0403 presented at: 13th European Congress of Clinical Microbiology and Infectious Diseases; May 10-13, 2003; Glasgow, UK.
52. Schranz JA, Krause D, Goldstein BP, Henkel T. Efficacy of anidulafungin (ANID) for the treatment of candidemia. Abstract M-971 presented at:. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL.
53. Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother. 2004;48:2021-2024.
54. Pfaller MA, Diekema DJ, Boyken L, et al. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob Agents Chemother. 2005;49:4795-4797.
55. ClinicalTrials.gov. Safety, tolerance and pharmacokinetics of anidulafungin in immunocompromised children ages 2-17. Available at: . Accessed April 10, 2006.
56. Thye D, Shepherd B, White RJ, Weston IE, Henkel T. Anidulafungin: a phase 1 study to identify the maximum tolerated dose in healthy volunteers. Abstract A-36 presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, IL.
57. Thye D, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: safety and pharmacokinetics in subjects receiving concomitant cyclosporine. Abstract A-1836 presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, CA.
58. Dowell JA, Stogniew M, Krause D, Henkel T, Weston IE. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol. 2005;45:227-233.
59. White RJ, Thye D. Anidulafungin does not affect the metabolism of cyclosporin by human hepatic microsomes. Abstract A-35 presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, IL.
60. Dowell JA, Schranz J, Baruch A, Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol. 2005;45:1373-1382.
61. Dowell JA, Schranz J, Buckwalter M, Stogniew M, Krause D. Safety and pharmacokinetics of co-administered anidulafungin and tacrolimus. Abstract 501451 presented at: 45th Interscience Conference on Antimicrobial Agents and Chemoterapy; December 16-19, 2005; Washington DC.
62. Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health Syst Pharm. 2005;62:834-837.